Evidence map›Paper›PMID 25995225›Full record

ArticleScience translational medicine2015

The αvβ1 integrin plays a critical in vivo role in tissue fibrosis.

Nilgun I Reed, Hyunil Jo, Chun Chen, Kazuyuki Tsujino, Thomas D Arnold, William F DeGrado, Dean Sheppard

Open access · bronzeAbstract read
In one paragraph

Article in Science translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed
17.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 294 citations in OpenAlex.

  1. Bexotegrast Shows Dose-Dependent Integrin αAnnals of the American Thoracic Society · 2025
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. The emerging role of integrin signaling in pulmonary vascular disease.American journal of physiology. Lung cellular and molecular physiology · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis.Seminars in respiratory and critical care medicine · 2025
    Review
  16. Review
  17. Chest Imaging with a Collagen-Binding Probe-A Human Hydroxyproline Assay?American journal of respiratory and critical care medicine · 2025
    Article
  18. Review
  19. Article
  20. Article

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nilgun I ReedDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Hyunil JoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94143, USA.
Chun ChenDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Kazuyuki TsujinoDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Thomas D ArnoldDepartment of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA.
William F DeGradoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94143, USA. dean.sheppard@ucsf.edu bill.degrado@ucsf.edu.
Dean SheppardDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA. dean.sheppard@ucsf.edu bill.degrado@ucsf.edu.
University of California, San Francisco · US

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 1986 to 2026
$30.7M
Targeting Epithelial Cells To Treat Pulmonary FibrosisP01HL108794 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PAPA, FEROZ R · 2012 to 2016
$12.6M
In Vivo Function of Pulmonary IntegrinsR37HL053949 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHEPPARD, DEAN · 2007 to 2013
$2.7M
IN VIVO FUNCTIONS OF PULMONARY INTEGRINSR01HL053949 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHEPPARD, DEAN · 1995 to 2006
$2.5M
Treatment of pulmonary fibrosis with inhibitors of integrin alphavbeta1.UH2HL123423 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEGRADO, WILLIAM, SHEPPARD, DEAN · 2014 to 2015
$2.2M
NHLBI NIH HHS HL108794NHLBI NIH HHS HL53949NHLBI NIH HHS P01 HL108794NHLBI NIH HHS R01 HL053949NHLBI NIH HHS R37 HL053949NHLBI NIH HHS UH2 HL123423NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

Integrins are transmembrane heterodimeric receptors that contribute to diverse biological functions and play critical roles in many human diseases. Studies using integrin subunit knockout mice and inhibitory antibodies have identified important roles for nearly every integrin heterodimer and led to the development of a number of potentially useful therapeutics. One notable exception is the αvβ1 integrin. αv and β1 subunits are individually present in numerous dimer pairs, making it challenging to infer specific roles for αvβ1 by genetic inactivation of individual subunits, and αvβ1 complex-specific blocking antibodies do not yet exist. We therefore developed a potent and highly specific small-molecule inhibitor of αvβ1 to probe the function of this understudied integrin. We found that αvβ1, which is highly expressed on activated fibroblasts, directly binds to the latency-associated peptide of transforming growth factor-β1 (TGFβ1) and mediates TGFβ1 activation. Therapeutic delivery of this αvβ1 inhibitor attenuated bleomycin-induced pulmonary fibrosis and carbon tetrachloride-induced liver fibrosis, suggesting that drugs based on this lead compound could be broadly useful for treatment of diseases characterized by excessive tissue fibrosis.

Indexed as

Signal TransductionAnimalsBleomycinCells, CulturedChemical and Drug Induced Liver InjuryDrug DesignFibroblastsHydrocarbons, BrominatedLiverLiver Cirrhosis, ExperimentalLungMiceMice, Inbred C57BLMolecular Targeted TherapyPulmonary FibrosisReceptors, VitronectinBleomycincarbon tetrabromideHydrocarbons, Brominatedintegrin alphavbeta1Receptors, VitronectinTransforming Growth Factor beta

Identifiers

PMID25995225
PMCPMC4461057
OpenAlexW2159360181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.